Appel urgent de la société civile : du cannabis médical pour nos aînés ! Nous, associations d’usagers de cannabis à des fins thérapeutiques, médecins et travailleurs sociaux dans le champ des addictions, militants humanitaires appelons solennellement le ministre de la Santé, Olivier Véran, le gouvernement d’Edouard Philippe et le Président de la République, Emmanuel Macron, à rendre possible l’accès immédiat au cannabis à usage médical. Comme l’ont expliqué William Lowenstein et Jean-Yves Nau (Slate du 16 avril 2020), il est choquant que nos anciens reçoivent force benzodiazépines, antidépresseurs, neuroleptiques et opioïdes sans même que l’accès au cannabis à usage thérapeutique soit possible en [...]
Lire la suiteHigh Times for Painful Blues : The Endocannabinoid System in Pain-Depression Comorbidity Marie Fitzgibbon, David P. Finn, Michelle Roche International Journal of Neuropsychopharmacology, 2016, 19, (3), 1–20 doi : 10.1093/ijnp/pyv095 Abstract Depression and pain are two of the most debilitating disorders worldwide and have an estimate co-occurrence of up to 80%. Comorbidity of these disorders is more difficult to treat, associated with significant disability and impaired healthrelated quality of life than either condition alone, resulting in enormous social and economic cost. Several neural substrates have been identified as potential mediators in the association between depression and pain, including neuroanatomical reorganization, monoamine and neurotrophin depletion, dysregulation [...]
Lire la suiteConfinement et cannabis, cachez cette addiction que le gouvernement ne saurait voir Jean-Yves Nau — 2 avril 2020 à 7h00 http://www.slate.fr/story/189123/addictions-cannabis-confinement-coronavirus-deni-consequences-dependance Tabac, alcool et produits de vapotage n'ont heureusement pas été interdits. Mais il va falloir compter avec les multiples conséquences de la pénurie en cannabis. «Une dépendance grave à une substance licite vaut toujours mieux qu'une dépendance de moindre gravité à une substance interdite», déplore le Dr William Lowenstein, président de SOS Addictions. | realworkhard, ponce_photography et gjbmiller via Pixabay Il croyait très bien faire. Lundi 23 mars, Ziad Khoury, préfet de l'Aisne, prenait un arrêté interdisant toutes les ventes d'alcool à emporter dans l'ensemble du [...]
Lire la suiteCannabis use and the course and outcome of major depressive disorder : A population based longitudinal study FEINGOLD D., REHM J., LEV-RAN S. Psychiatry Research, 2017, 251, 225-234. Doi : 10.1016/j.psychres.2017.02.027 Highlights • Individuals with baseline major depressive disorder were followed over a three-year time period. • Cannabis users and individuals with cannabis use disorders were compared to nonusers. • No differences were found in rates of remission between the groups. • Level of cannabis use was associated with significantly more depressive symptoms at follow-up. • These findings did not retain significance after adjusting for baseline confounding factors. Abstract Cannabis use has been reported to affect [...]
Lire la suiteCannabis Use and Cognition in Adults Prescribed Opioids for Persistent Pain Megan Wildes, Teresa L. Bigand, Matthew E. Layton, , Marian Wilson Pain Management Nursing, 2019, 1-6. Doi : 10.1016/j.pmn.2019.06.014 a b s t r a c t Background : Adults with persistent pain frequently report cannabis use to help manage their symptoms. The impact of cannabis use on cognition in the presence of concurrent symptoms of depression and anxiety is poorly understood. Aims : Our study explored how cannabis use affects relationships among symptoms of depression, anxiety, and cognition. Design : A cross-sectional survey study was conducted. Settings : Surveys were distributed at outpatient clinics treating adults [...]
Lire la suiteCannabis Use Moderates the Relationship between Pain and Negative Affect in Adults with Opioid Use Disorder Marian Wilson, Hannah Y. Gogulski, Carrie Cuttler, Teresa L. Bigand, Oladunni Oluwoye,Celestina Barbosa-Leiker, MaryLee A. Roberts Addictive Behaviors, 2017, 30 p. doi : 10.1016/j.addbeh.2017.10.012 Abstract Introduction : Adults in Medication-Assisted Treatment (MAT) for opioid addiction are at risk for substance use relapse and opioid overdose. They often have high rates of cannabis use and comorbid symptoms of pain, depression, and anxiety. Low levels of self-efficacy (confidence that one can self-manage symptoms) are linked to higher symptom burdens and increased substance use. The effects of cannabis use on symptom management [...]
Lire la suiteBibliographie : Cannabidiol (CBD) Docteur Christian SUEUR, GRECC, avril 2020. voir aussi : Bibliographie : Cannabis et Cannabinoïdes en Psychiatrie, Bibliographie : Cannabinoïdes et neuroprotection Bibliographie : Cannabinoïdes et épilepsie Bibliographie : Interactions et antagonisme THC - CBD Bibliographie : Effets indésirables du Cannabis (thérapeutique) sur la Santé mentale Bibliographie : Cannabinoïdes, Dépression et Troubles de l’Humeur Bibliographie : Cannabinoïdes et PTSD Bibliographie : Cannabinoïdes et TSA/TED/psychoses infantiles Bibliographie : Cannabinoïdes et Maladies Neurodégénératives
Lire la suiteThe Effect of a Single Dose of Intravenous Ketamine on Suicidal Ideation: A Systematic Review and Individual Participant Data Meta-Analysis Samuel T. Wilkinson, M.D., Elizabeth D. Ballard, Ph.D., Michael H. Bloch, M.D., M.S., Sanjay J. Mathew, M.D., James W. Murrough, M.D., Ph.D., Adriana Feder, M.D., Peter Sos, M.D., Ph.D., Gang Wang, M.D., Carlos A. Zarate, Jr., M.D., Gerard Sanacora, M.D., Ph.D. American Journal of Psychiatry, 2018, 175, (2) 150–158. Doi : 10.1176/appi.ajp.2017.17040472 Objective : Suicide is a public health crisis with limited treatment options. The authors conducted a systematic review and individual participant data meta-analysis examining the effects of a single dose of ketamine [...]
Lire la suiteRethinking Therapeutic Strategies for Anorexia Nervosa: Insights From Psychedelic Medicine and Animal Models Claire J. Foldi, Paul Liknaitzky, Martin Williams, Brian J. Oldfield Frontiers in Neuroscience, 2020 | Volume 14 | Article 43 : 1-8 doi : 10.3389/fnins.2020.00043 Anorexia nervosa (AN) has the highest mortality rate of any psychiatric disease, yet available pharmacological treatments are largely ineffective due, in part, to an inadequate understanding of the neurobiological drivers that underpin the condition. The recent resurgence of research into the clinical applications of psychedelic medicine for a range of mental disorders has highlighted the potential for classical psychedelics, including psilocybin, to alleviate symptoms of AN [...]
Lire la suitePsychedelics for Mental Illness: The Evidence to Date Todd Murphy Medscape, 12 March, 2020. https://www.medscape.com/viewarticle/926694_print Psychedelic drugs show real promise as treatment for psychiatric illnesses, particularly posttraumatic stress disorder (PTSD) as well as depression and anxiety, new research suggests. A literature review showed completed clinical trials support the efficacy of 3, 4-methylenedioxymethamphetamine (MDMA), commonly known by its street name of Ecstasy, to treat chronic PTSD. The review also confirmed that psilocybin, a compound contained in some species of mushrooms, significantly helped in the treatment of depression and cancer-related anxiety. Other promising, though more preliminary, results suggests that the hallucinogenic drug LSD (lysergic acid diethylamide) and a plant-based brew [...]
Lire la suite